Exoseal closure device
DeviceClosure device for femoral artery access closure
NCT Number: NCT02234830
Is the ExoSeal VSD non-inferior to Angio-Seal vascular closure device (VSD) in the incidence of adverse access site related events at 30 days.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Aarhus University Hospital, Aarhus N, Denmark
Prospective, randomized (1:1) controlled, single blind, single center study in 2000 percutaneous coronary intervention (PCI) patients comparing the ExoSeal VCD (test device) to the AngioSeal VCD (standard comparator). In-hospital and 30 days safety and efficacy endpoints and 6 months safety endpoints will be reported.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Closure device for femoral artery access closure
Closure device for femoral artery access closure
Time frame: 30 days
This includes: major bleeding and/or bleeding necessitating blood transfusion, pseudoaneurysm with indication for treatment, arteriovenous fistula, groin surgery and/or possible related vascular surgery, infection needing antibiotics.
Time frame: participants will be followed for the duration of hospital stay, an expected average of 2 days
Insignificant bleeding seen on the bandage or small continuous oozing is considered haemostasis. Continuous oozing will be counted as a Bleeding Academic Research Consortium (BARC) type 1 bleeding event
Time frame: 30 minutes
Combined endpoint of any mechanic failure, deployment failure and/or immediate profuse bleeding needing prolonged manual compression. Individual endpoints will be reported.
Time frame: 30 minuts
Time frame: 30 days
Time frame: Closure procedure and 30 days
Assessed on a numerical rating scale (NRS) from 0 (no pain or discomfort) to 10 (worst possible pain or discomfort) Scripted language will be used when discussing pain scores with the patient. Pain and discomfort score will be assessed just before and immediately after the closure procedure and reported. The delta-value will be reported and compared. The patient will be given predefined standardized instructions on how to rate and that only pain and discomfort related to the closure procedure should be assessed
Time frame: participants will be followed for the duration of hospital stay, an expected average of 2 days
From start of closure procedure to patient is mobilized. Patients treated for ST-elevation myocardial infarction are assessed separately
Time frame: participants will be followed for the duration of hospital stay, an expected average of 2 days
Larger than 5x5 cm measured by ruler in the catheterization laboratory and at discharge
Time frame: 30 days
Access site related and non-access site related
Time frame: 6 months
Time frame: 30 days and 6 months
Time frame: 30 days and 6 months
Time frame: 30 days and 6 months
Time frame: 30 days and 6 months
Time frame: 30 days
Aarhus University Hospital Skejby
Other
Acronym: CLOSE-UP II
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial DetailsNCT02579655
Brain Diseases, Cardiovascular Diseases
Calgary, Alberta, Canada
View Trial DetailsNCT04580017
Angina Pectoris, Angina, Unstable
Hammam Sousse, Sousse Governorate, Tunisia
View Trial DetailsNCT00248352
Arterial Occlusive Diseases, Arteriosclerosis
Ottawa, Ontario, Canada
View Trial Details